After reports of J&J and AstraZeneca jabs causing blood clots in rare cases, the Sputnik V developer said its vaccine doesn’t have such side effects and offered to share its technologies to help other producers solve this problem.

“A comprehensive analysis of adverse events during clinical trials and over the course of mass vaccinations with the Sputnik V vaccine showed that there were no cases of cerebral venous sinus thrombosis (CVST),” the Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology said on Wednesday.

The statement came a day after the US Food and Drug Administration (FDA) recommended to “pause” inoculations with the Johnson and Johnson (J&J) vaccine against Covid-19 after six of its recipients developed a “rare and severe type of blood clot” or CVST. Earlier, the same side effects prompted several countries to halt the use of the AstraZeneca jab, while others placed age limitations on it. On Wednesday, Denmark became the first European country to completely suspend the vaccine over the concerns.

Also on Danish drug regulator FAINTS at press conference announcing AstraZeneca vaccine halt (VIDEO)

The Gamaleya Research Institute stressed “there is no reason and no justification to extrapolate safety data” from J&J and AstraZeneca vaccines to Sputnik V, which boasts an efficacy of over 91%. The three immunizations might be based on adenoviral vector platforms, but they are all “different and not directly comparable” when it comes to their structure and the technologies used, it added. (RT)